The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.
The article “The T cell subsetting challenge” by Dr. Natalia R. Comet (Karolinska Institutet) and Prof. Carmen Gerlach (Head of Research Division “Tailored T-Cell Diversity” at the LIT), published in “Trends in Immunology”, explores the complexities and inconsistencies in defining and classifying T cell subsets.
In May 2025, the new dialogue format brought together members of the Bavarian State Parliament with researchers from the Leibniz Association, including LIT experts.
New Publication in Nature Cancer: Scientists from the LIT Cooperation Group “Translational Immunobiology of Early Systemic Cancer” and the LIT “Division of Immunology” give new insights into the initial steps of cancer spread in melanoma.
A passionate group of young scientists—many affiliated with the Leibniz Institute for Immunotherapy (LIT)—successfully brought the Pint of Science festival back to Regensburg in 2025, continuing a local tradition that they began in 2022.
LIT scientist Meghma Mukherjee, PhD student at the Research Division “Interventional Immunology” headed by Prof. Philipp Beckhove, received the Best Poster Award at the CIMT Annual Meeting in Mainz.
A recent Nature news piece examines the emerging science of mitochondrial transfer between cells and asks whether this process could be leveraged to treat cancer and other diseases. Among the leading experts in the field interviewed for this news piece is LIT scientist, Dr. Jeremy Baldwin, whose recent publication brought new attention to the discipline of organelle medicine.
We’re thrilled to have Prof. Carmen Gerlach join our team. She has been dedicated to understanding diversification within CD8+ T cell responses for 20 years. Her new research division “Tailored T-Cell Diversity” works on T cell immunotherapy of cancer and inflammatory diseases.
The daily newspaper Handelsblatt ranked iOmx as one of the five most promising biotech startups in Germany. iOmx was founded by Prof. Philipp Beckhove, Scientific Director of the Leibniz Institute for Immunotherapy (LIT), and Dr. Nisit Kandelwal in 2016.
A group of 18 PhD students of the Leibniz Institute for Immunotherapy (LIT) attended this year’s PhD retreat in the Bavarian Forest.
We are excited to welcome Dr. Leo Scheller to our team. He will head the new research group “Structural Biochemistry” at the LIT, which develops synthetic receptors and protein therapeutics to improve the safety and efficacy of immunotherapies.
